Alzamend Neuro (ALZN) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lantern Pharma is the larger company by market cap ($3.9 million vs $3.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | LTRN |
|---|---|---|
| Share price | $0.7758 | $0.245 |
| Market cap | $3.74M | $3.89M |
| 1-day change | -23.94% | -13.73% |
| YTD return | — | -91.91% |
| 1-year return | — | -91.89% |
| 5-year return | — | -97.27% |
| EPS (TTM) | $-2.30 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-8.77M | $-17.12M |
| 52-week high | $2.54 | $4.34 |
| 52-week low | $0.754 | $0.2286 |
| Distance from 52-week high | -69.40% | -94.35% |
| Analyst consensus | none | none |
| Avg. price target upside | +3251.38% | +7042.86% |
| Average volume | 70.27K | 249.66K |
| Shares outstanding | 4.83M | 15.89M |
| Employees | 4 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
ALZN vs LTRN FAQ
Which is bigger, Alzamend Neuro or Lantern Pharma?
Lantern Pharma (LTRN) is larger, with a market capitalization of $3.89M compared with $3.74M for Alzamend Neuro (ALZN).
Are Alzamend Neuro and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.